REBECCA CUMMINGS: Open Payments
NPI 1083013015 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$626 in 28 payments from 10 companies in 2025. Trend: 2023 $56 · 2024 $605 · 2025 $626
Food & beverage: $626
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 7 | $171 |
| PFIZER INC. | 5 | $108 |
| Abbott Laboratories | 4 | $103 |
| Novo Nordisk Inc | 4 | $60 |
| SANOFI-AVENTIS U.S. LLC | 2 | $57 |
| Lilly USA, LLC | 2 | $32 |
| Merck Sharp & Dohme LLC | 1 | $30 |
| Medtronic, Inc. | 1 | $24 |
| GlaxoSmithKline, LLC. | 1 | $20 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $20 |
Products named: LEQVIO, PREVNAR 20, FREESTYLE LIBRE 3, Wegovy, TZIELD, CAPVAXIVE, SYMPLICITY G3, AREXVY.
Industry payments across TX — which companies pay providers there.
